An aptamer ligand based liposomal nanocarrier system that targets tumor endothelial cells

Abstract

23The objective of this study was to construct our recently developed aptamer-modified 24 targeted liposome nano-carrier (Apt-PEG-LPs) system to target primary cultured mouse

Nanoparticle-conjugated aptamer targeting hnRNP A2/B1 can recognize multiple tumor cells and inhibit their proliferation

“…Currently, the promising classes of aptamer-conjugated nanomaterials in fields of tumor therapy included aptamer-conjugated polymeric (liposomes [30], micelles [31], and organic polymeric nanoparticles [32] etc. ), and inorganic nanoparticles (magnetic nanoparticles [33], silica nanoparticles [34], quantum dots [35], graphene oxide nanosheets [36], carbon tubes, etc.).…”

In vitro study of novel gadolinium-loaded liposomes guided by GBI-10 aptamer for promising tumor targeting and tumor diagnosis by magnetic resonance imaging

“…Many initial studies using aptamers as delivery systems have produced exciting results as well. 3,4,[10][11][12][13][17][18][19][20] However, to realize the full potential of aptamer-targeted delivery systems, it is necessary to test for aptamers that are specific for clinically relevant cancer markers and demonstrate the effectiveness of the systems in vivo. Enormous progress has been made in the field in a very short period of time.…”

“…[5][6][7] In comparison to Abs, aptamers possess several obvious advantages. They are generally considered nonimmunogenic and biocompatible, much more stable to heat, pH, and organic solvents, easier to prepare and scale up, and with smaller molecular weight (8)(9)(10)(11)(12)(13)(14)(15). 3,8 The ssDNA or ssRNA can fold into welldefined 3D-structures and bind to their target with high affinity (μM-pM range) and specificity.…”

“…3,8 The ssDNA or ssRNA can fold into welldefined 3D-structures and bind to their target with high affinity (μM-pM range) and specificity. 10 Furthermore, aptamers can be chemically modified to enhance their stability and affinity with targets.…”

“…3,4,[10][11][12][13] In 2004, FDA-approved Macugen (pegaptanib) as an antiangiogenic therapeutic agent for neovascular (wet) age-related macular degeneration. In addition, a variety of other aptamers, such as AS1411, are currently under clinical trials.…”